It’s cybersecurity awareness month and our cybersecurity partner Mitigo are sharing helpful advice and guidance. This week they are helping practices with a strategy to defend against ransomware attacks. This guide highlights the five layers of defence that you should have lined up against this threat to keep your business secure.
Blog
Guest blog post by RSM
Guest blog post by Mitigo
Cyber breaches are not acts of God. They are preventable, provided you have taken the right steps to protect your business from attack. The central theme of this article is that the only way to prove to yourself and your senior leadership team that you have put the right defences in place, is to obtain independent assurance.
What is assurance?
Guest blog by Sabrina Griffin, Region Market Development Manager, Life Sciences and Laboratory Products Group at Thermo Fisher Scientific
Guest blog by Guy Kaddish, Bidwells Planning Partner
Guest blog post by RSM
What are the key business risks in healthcare and life sciences?
Guest blog post by Dr. Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategic Lead, Thermo Fisher Scientific
A recent blog post from AMSBIO introduces a selection of the ‘green products’ it offers to life science researchers looking to maintain rigorous scientific standards in their lab whilst also trying to minimize environmental impact.
Laboratories are known to consume a significant amount of energy and produce a considerable amount of waste. However, with the increasing awareness of the importance of sustainability, many life sciences labs are taking steps towards prioritizing sustainable products and practices.
Guest Blog: Ahead of BioBeat23, Miranda Weston-Smith, BioBeat founder, talks to Alisa Molotova, Investment Manager at Martlet and co-organiser of BioBeat23 about her investment journey.
Miranda: It’s a total pleasure working with you on BioBeat23: Out of adversity comes opportunity on 18 May at the Cambridge Union. I’m curious to know, how did you get into biotech investing?
There is no doubt that AI is a revolution underway, not just in healthcare, but across a broad range of industries. Although, continuing improvements in technology capabilities, such as computing power, and access to data are creating more opportunities for the application of AI in the drug discovery process, Pharma still lags behind other industries for AI adoption.